Novartis and Roche get NICE rejections
There was disappointing news today for Swiss pharma giants Novartis (NOVN: VX) and Roche (ROG: SIX) when the UK’s National Institute for Health and Care Excellence (NICE) published draft guidance on technology appraisals turning down drugs from the companies for regular use on the National Health Service (NHS).
The medicines cost-effectiveness watchdog announced that tocilizumab, marketed by Roche under the brand name RoActemra in Europe, is not recommended to treat giant cell arteritis (GCA).
The committee concluded that there were substantial uncertainties in the evidence about how long patients would have to take the treatment and what the long-term benefits were.
The cost effectiveness estimate for tocilizumab was significantly higher than the range normally considered acceptable for use in the NHS.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze